Recombinant Human PI 3 Kinase p85 (SH2) protein (GST tag N-Terminus)
Be the first to review this product! Submit a review
|
(0 Publication)
Recombinant Human PI 3 Kinase p85 (SH2) protein (GST tag N-Terminus) is a Human Full Length protein, in the 1 to 454 aa range, expressed in Wheat germ, suitable for ELISA, WB.
View Alternative Names
GRB1, PIK3R1, Phosphatidylinositol 3-kinase regulatory subunit alpha, PI3-kinase regulatory subunit alpha, PI3K regulatory subunit alpha, PtdIns-3-kinase regulatory subunit alpha, Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha, PI3-kinase subunit p85-alpha, PtdIns-3-kinase regulatory subunit p85-alpha
- SDS-PAGE
Unknown
SDS-PAGE - Recombinant Human PI 3 Kinase p85 (SH2) protein (GST tag N-Terminus) (AB159130)
ab159130 on a 12.5% SDS-PAGE stained with Coomassie Blue.
Reactivity data
Sequence info
Properties and storage information
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
PI 3 Kinase p85 acts to stabilize the catalytic subunit allowing for proper signal transduction in response to external stimuli. As part of the PI3K complex it is essential for the regulation of the enzyme's substrate specificity and activity. This complex facilitates the conversion of PIP2 to PIP3 a lipid second messenger that is important in various signalling pathways. Through its actions PI 3 Kinase p85 supports cell proliferation differentiation and metabolism impacting numerous cellular processes.
Pathways
PI 3 Kinase p85 plays significant roles within the PI3K/AKT and mTOR signaling pathways. These pathways are fundamental to regulating processes like cell metabolism apoptosis and protein synthesis. In the PI3K/AKT pathway the p85 subunit collaborates closely with the catalytic p110 subunit to phosphorylate and activate AKT an important downstream effector. In the mTOR pathway it influences cellular response to growth factors. These interactions of PI 3 Kinase p85 with other proteins display its centrality to critical cellular activities.
Specifications
Form
Liquid
General info
Function
Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed : 17626883, PubMed : 19805105, PubMed : 7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed : 20348923).
Sequence similarities
Belongs to the PI3K p85 subunit family.
Post-translational modifications
Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.. In adipose tissue, polyubiquitinated by the BCR(KBTBD2) E3 ubiquitin ligase complex; recognized by KBTBD2 through the SH2 domains, undergoes 'Lys-48'-linked polyubiquitination leading to its degradation.. Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear (By similarity). Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR.
Target data
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com